- Home
- PIII vs TRIB Comparison
PIII vs TRIB Comparison
Compare PIII & TRIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PIII | TRIB |
|---|---|---|
| Founded | 2015 | 1992 |
| Country | United States | Ireland |
| Employees | N/A | N/A |
| Industry | Medical/Nursing Services | Biotechnology: In Vitro & In Vivo Diagnostic Substances |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 17.1M | 18.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | PIII | TRIB |
|---|---|---|
| Price | $4.21 | $0.89 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $16.25 | N/A |
| AVG Volume (30 Days) | 10.7K | ★ 114.2K |
| Earning Date | 11-13-2025 | 03-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $1,444,952,000.00 | $61,555,000.00 |
| Revenue This Year | N/A | $13.51 |
| Revenue Next Year | $12.27 | $13.14 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 8.31 |
| 52 Week Low | $4.01 | $0.48 |
| 52 Week High | $14.50 | $3.44 |
Technical Indicators
Market Signals| Indicator | PIII | TRIB |
|---|---|---|
| Relative Strength Index (RSI) | 21.04 | 42.22 |
| Support Level | $5.01 | $0.88 |
| Resistance Level | $5.20 | $1.05 |
| Average True Range (ATR) | 0.22 | 0.11 |
| MACD | -0.01 | -0.01 |
| Stochastic Oscillator | 2.48 | 5.69 |
Price Performance
Historical ComparisonAbout PIII P3 Health Partners Inc.
P3 Health Partners Inc is a patient-centered and physician-led population health management company. P3's model aggregates and supports the community's existing healthcare resources to build a network of community providers working together to deliver coordinated and integrated care to patients with a shared commitment to improving patient outcomes, lowering cost, and delivering experience for all.
About TRIB Trinity Biotech plc
Trinity Biotech PLC is in the business of developing, manufacturing, and marketing clinical diagnostic products for clinical laboratory and point-of-care sections of the diagnostic market. Its products are used to detect autoimmune, infectious, sexually transmitted diseases, diabetes, and disorders of the liver and intestine. The company also provides raw materials to the life sciences and research industries globally. It markets products under the brand names Recombigen, Unigold, MarBlot, Mardx, Immublot, and others. Geographically, it has two segments namely the Americas, and the Rest of World - Ireland from which it derives a majority of its revenue from the Americas segment.